Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event: persistent perforation · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Hearing ‐ mean final hearing threshold (4 months ‐ medium‐term) № of participants: 125 (1 RCT) · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Self‐reported shoulder function: Croft Shoulder Disability Score (1 or more problems) · adults with minimally displaced or displaced (2‐part or 3‐part) proximal humeral fractures treated non‐surgically (5 trials)
It is very uncertain whether early changes self‐reported shoulder function: Croft Shoulder Disability Score (1… compared with delayed mobilisation (very low certainty).
2 findings from 1 review
Functional outcomes · (mainly older) adults with most types of displaced proximal humeral fracturesa (10 trials)
Surgical showed no clear difference in functional scoresf(higher = better outcome) compared with non‐surgical treatment (high certainty).
3 findings from 1 review
SMD 0.06
5 studies · 423 participants
High
SMD 0.1
7 studies · 552 participants
High
SMD 0.17
3 studies · 347 participants
Moderate
Quality of life: EQ‐5D (0: dead to 1: best quality of life) · (mainly older) adults with most types of displaced proximal humeral fracturesa (10 trials)
Surgical showed no clear difference in quality of life: EQ‐5D (0: dead to 1: best quality of life) compared with non‐surgical treatment (high certainty).
1 finding from 1 review
All‐cause mortality · (mainly older) adults with most types of displaced proximal humeral fracturesa (10 trials)
Surgical showed no clear difference in mortality compared with non‐surgical treatment (low certainty).
1 finding from 1 review
Reoperation · (mainly older) adults with most types of displaced proximal humeral fracturesa (10 trials)
Surgical may leads to higher additional surgery (reoperation or secondary surgery) compared with non‐surgical treatment (low certainty).
1 finding from 1 review
Adverse events / complications ‐ Number of participants with complications · (mainly older) adults with most types of displaced proximal humeral fracturesa (10 trials)
Surgical showed no clear difference in adverse events / complications ‐ Number of participants with… compared with non‐surgical treatment (low certainty).
1 finding from 1 review
Self‐reported shoulder function · adults with minimally displaced or displaced (2‐part or 3‐part) proximal humeral fractures treated non‐surgically (5 trials)
1 finding from 1 review
Quality of life: EQ‐5D (0: dead to 1: best quality of life) · adults with minimally displaced or displaced (2‐part or 3‐part) proximal humeral fractures treated non‐surgically (5 trials)
1 finding from 1 review
All‐cause mortality · adults with minimally displaced or displaced (2‐part or 3‐part) proximal humeral fractures treated non‐surgically (5 trials)
1 finding from 1 review
Adverse events: Shoulder complications · adults with minimally displaced or displaced (2‐part or 3‐part) proximal humeral fractures treated non‐surgically (5 trials)
1 finding from 1 review
Additional surgery or substantive treatment · adults with minimally displaced or displaced (2‐part or 3‐part) proximal humeral fractures treated non‐surgically (5 trials)
1 finding from 1 review
Red blood cell transfusions (Subnet based on 69 studies including 18,684 participants) · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review
Blood products transfused (RBC) % of patients · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes blood products transfused (RBC) % of patients compared with FVIIa (very low certainty).
1 finding from 1 review
All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes thrombotic events compared with FVIIa (very low certainty).
1 finding from 1 review
Mortality (30‐day) · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes mortality (30‐day) compared with FVIIa (very low certainty).
1 finding from 1 review
Bleeding (chest drain output) in mLs for the first 12 hours · cardiac surgery for the treatment of non‐surgical bleeding
1 finding from 1 review